Document Detail


Intravitreal Anti VEGF Drugs as Adjuvant Therapy in Diabetic Retinopathy Surgery.
MedLine Citation:
PMID:  21438852     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The use of intravitreal anti vascular endothelial growth factor (anti-VEGF) drugs such as pegaptanib, ranibizumab and bevacizumab has been widely reported to treat complications such as macular edema and rubeosis. During the past few years they have also been used as an adjuvant therapy to reduce intraocular bleeding during vitrectomy in eyes with proliferative diabetic retinopathy as well as to reduce the occurrence of vitreous haemorrhages in vitrectomized eyes and facilitate glaucoma surgery. In this paper we review the use of anti VEGF drugs in the surgical management of diabetic retinopathy related complications.
Authors:
Javier A Montero; José M Ruiz-Moreno; Maria Encarnacion Correa
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-24
Journal Detail:
Title:  Current diabetes reviews     Volume:  -     ISSN:  1875-6417     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101253260     Medline TA:  Curr Diabetes Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Retina Section, Pio del Rio Hortega University Hospital, Valladolid, Spain. javmonmor@hotmail.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives.
Next Document:  A stellar new surgical approach for nystagmus-induced head turn.